Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Conatumumab and Ganitumab
NCT01327612Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2011
- Primary completion
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of conatumumab, ganitumab in solid tumor (advanced stage), Carcinoid Tumor (CT), colorectal cancer (CRC), lymphoma, metastatic cancer, sponsored by Amgen. Started Mar 2011; status: completed.
02
Drugs
conatumumabganitumab
03
Conditions
solid tumor (advanced stage)Carcinoid Tumor (CT)colorectal cancer (CRC)lymphomametastatic cancer
Beyond the preview
Go deeper on NCT01327612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01327612.